Effectiveness of V-Go™ for Patients With Diabetes in a Real-world Setting
SIMPLE
SIMPLE
Sponsor study identifier
observational
270
1 country
25
Study Start
January 2012
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
March 2014
Actual (reported)Study Completion
May 2014
Actual (reported)The aim of the present study is to observe glycemic control, dose requirements, hypoglycemia risk, other possible adverse effects and weight changes, as well as to compare these parameters to prior treatment when patients with type 2 diabetes are initiated and treated using V-Go during circumstances as close to normal clinical practice as possible.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
May 2014
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 3, 2011
Actual (reported)March 31, 2011
Actual (reported)January 2012
Date type not reportedThis date has not been verified as actual or estimated.
March 2014
Actual (reported)May 2014
Actual (reported)The primary objective is to compare change of average glycemic control as measured by A1C from baseline to the end of V-Go use for the whole cohort as well as each of the five categories of baseline treatment.
12 month
Glycemic control is measured by the HbA1C from the beginning of the study to the end.
12 month
To describe the incidence of hypoglycemia in participants as measured by blood glucose of <70 mg/dl.
12 month
Number of Participants with adverse events.
12 month
How well the participants follow their doctors prescriptions for diabetes care.
12 month
To describe insulin dose requirements from the beginning to the end of the study , and concomitant drugs to lower blood glucose.
12 month
Use of Insulin Delivery Device, V-Go, and the effect on A1C for T2DM patients in five categories of baseline oral antidiabetes drug (OAD) use with or without insulin.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Type 2 Diabetes Mellitus
San Diego Coastal Endocrinology Group
Chula Vista, California, 91911, United States
Nancy J. Bohannon Med. Corp
San Francisco, California, 94110, United States
Western Connecticut Health Network, Inc.
Danbury, Connecticut, 06810, United States
MEDSOL Clinical Research Center
Port Charlotte, Florida, 33952, United States
Atlanta Diabetes Associates
Atlanta, Georgia, 30309, United States
Albert Johary M.D., P.C.
Dunwoody, Georgia, 30338, United States
Endocrine Research Solutions, Inc.
Grunberger G, Rosenfeld CR, Bode BW, Abbott SD, Nikkel C, Shi L, Strange P. Effectiveness of V-Go(R) for Patients with Type 2 Diabetes in a Real-World Setting: A Prospective Observational Study. Drugs Real World Outcomes. 2020 Mar;7(1):31-40. doi: 10.1007/s40801-019-00173-8.
Nancy J. Bohannon, MD
Nancy J. Bohannon Med. Corp
David Huffman, MD
University Diabetes & Endocrine Consultants
George Grunberger, MD
Grunberger Diabetes Institute
Kenneth Hershon, MD
North Shore Diabetes & Endocrine Assoc.
270 participants (actual enrollment reported by the registry).
First Submitted
March 3, 2011
First Posted
March 31, 2011
Study Start
January 2012
Date type not reportedThis date has not been verified as actual or estimated.
Impact of a Diabetes Transitions Tool Kit on Post-Hospitalization Glycemic Control
Contact the study team to confirm eligibility.
Roswell, Georgia, 30076, United States
MidAmerica Diabetes Associates
Wichita, Kansas, 67211, United States
MODEL Clinical Research
Baltimore, Maryland, 21204, United States
Grunberger Diabetes Institute
Bloomfield Hills, Michigan, 48302, United States
North Jersey Endocrine Consultants, LLCAND
Denville, New Jersey, 07834, United States
Parsippany Endocrine, LLC
Parsippany, New Jersey, 07054, United States
Regional Endocrinology Associates, PC
Santa Fe, New Mexico, 87505, United States
North Shore Diabetes & Endocrine Assoc.
New Hyde Park, New York, 11042, United States
Endocrine Associates of Long Island, PC
Smithtown, New York, 11787, United States
Middle Country Endocrinology, P.C.
Smithtown, New York, 11787, United States
University Physicians Group
Staten Island, New York, 10301, United States
Physicians East, PA
Greenville, North Carolina, 27834, United States
Diabetes & Endocrinology Consultants
Morehead City, North Carolina, 28557, United States
Down East Medical Associates
Morehead City, North Carolina, 28557, United States
PMG Research of Winston-Salem
Winston-Salem, North Carolina, 27103, United States
Alan B. Schorr, DO FACE
Langhorne, Pennsylvania, 19047, United States
PMG Research of Bristol
Bristol, Tennessee, 37620, United States
University Diabetes & Endocrine Consultants
Chattanooga, Tennessee, 37403, United States
PMG Research of Knoxville
Knoxville, Tennessee, 37919, United States
Chip Reed, MD
Endocrine Research Solutions, Inc.
Cheryl Rosenfeld, DO
North Jersey Endocrine Consultants, LLCAND
Alan B. Schorr, DO
Alan B. Schorr, DO FACE
Mark Warren, MD
Physicians East, PA
Richard A. Guthrie, MD
MidAmerica Diabetes Associates
Lenita Hanson, MD
MEDSOL Clinical Research Center
Philip A. Levin, MD
MODEL Clinical Research
Michael Shanik, MD
Endocrine Associates of Long Island, PC
Kathryn Jean Lucas, MD
Diabetes & Endocrinology Consultants
Mary Katherine Lawrence, MD
Down East Medical Associates
Sherry Sussman, MD
Middle Country Endocrinology, P.C.
Robert Bernstein, MD
Regional Endocrinology Associates, PC
Albert Johary, MD
Albert Johary M.D., P.C.
Jeffrey Rothman, MD
University Physicians Group
Robert Savino, DO
Western Connecticut Health Network, Inc.
Sarah Khan, MD
Parsippany Endocrine, LLC
Jonathan Wilson, DO
PMG Research of Winston-Salem
Stephanie Powell, MD
PMG Research of Bristol
Rickey Manning, MD
PMG Research of Knoxville
Georges M. Argoud, MD
San Diego Coastal Endocrinology Group
Primary Completion
March 2014
Actual (reported)Study Completion
May 2014
Actual (reported)Last Updated
June 2, 2015
Record last verified: 2015-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: